Sarepta Therapeutics Inc (SRPT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sarepta Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 14.90 $ — 0% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 33.1% passed
- More than 10% revenue growth is expected for the coming year -22.5% failed
- Share count grows by less than 3% a year 6.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1.6% failed
- Gross margin at 40% or higher and without meaningful erosion 59.9% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 102 m failed
- Return on capital at 15% or higher, or up versus two years ago -29.2% failed
- Insiders hold at least 10% or are net buyers 4.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 48.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 26
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.79 | 3.45 – 6.30 | 1,840 | 194.8% | 11 |
| 12/31/2027 | 2.45 | 0.98 – 4.02 | 1,409 | -48.9% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.34 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.47 | 239.10 | 658 | 65.90 | 24.20 | 92 | 54 |
| 2025: Q1 | -4.60 | -1,361.30 | 745 | 80.20 | -60.10 | -583 | -629 |
| 2025: Q2 | 1.85 | 2,734.10 | 611 | 68.40 | 32.20 | 261 | 229 |
| 2025: Q3 | -1.80 | -636.50 | 399 | -14.50 | -45.10 | -15 | -43 |
| 2025: Q4 | -2.70 | -284.10 | 443 | -32.70 | -63.90 | 131 | 125 |
| 2026: Q1 | 2.71 | – | 731 | -1.90 | 45.30 | -203 | -206 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 5 | -267 | -267 | -5.49 | -246 | 337 | 424 |
| 2017 | 155 | -172 | -51 | -0.86 | -232 | 789 | 1,308 |
| 2018 | 301 | -344 | -362 | -5.46 | -389 | 1,032 | 1,642 |
| 2019 | 381 | -706 | -715 | -9.71 | -456 | 818 | 1,823 |
| 2020 | 540 | -564 | -554 | -7.11 | 107 | 762 | 2,985 |
| 2021 | 702 | -460 | -419 | -5.15 | -443 | 928 | 3,148 |
| 2022 | 933 | -536 | -703 | -8.03 | -325 | 385 | 3,128 |
| 2023 | 1,243 | -268 | -536 | -5.80 | -501 | 859 | 3,265 |
| 2024 | 1,902 | 218 | 235 | 2.18 | -206 | 1,528 | 3,963 |
| 2025 | 2,198 | -658 | -713 | -6.81 | -205 | 1,141 | 3,350 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Sarepta Therapeutics, Inc., ein biopharmazeutisches Unternehmen in der kommerziellen Phase, konzentriert sich auf Entdeckung und Entwicklung von RNA-gerichteten Therapeutika, einer siRNA-Plattform, Gentherapie und anderen genetischen Therapiemodalitäten zur Behandlung seltener Erkrankungen.
| Employees | 835 |
|---|---|
| Headquarters | Cambridge, MA |
| Address | 215 First Street, 02142 Cambridge, United States |
| Phone | 617 274 4000 |
| Website | sarepta.com |
| IPO Date | 3. Jun 1997 |
| ISIN | US8036071004 |
| Stock Split | 1:6 on 07/12/2012 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 1978 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 28. Jul 2026 | Severino Michael | Chief Executive Officer | Other | 756,104 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.